Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults

Bidyut Kumar Das, S. Mishra, P. K. Padhi, Manish Ramesh, Rina Tripathy, P. K. Sahoo, B. Ravindran

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Fifty-two adult patients with cerebral malaria were randomly categorized into two groups to receive either quinine dihydrochloride (Qn) alone or a combination of Qn and pentoxifylline (Px). Thirty-two of them received intravenous (i.v.) Qn (group I), and 20 patients (group II) received i.v. Qn along with parenteral Px support (10 mg/kg/day) for the initial 3 days. There was significant improvement in coma resolution time in group II (21.6 ± 13.9 h) in comparison with group I (63.5 ± 19.7 h) (P < 0.001), and mortality was 25% of patients in group I against 10% patients receiving Px adjunct (P > 0.05). Three days post-therapy, serum tumour necrosis factor-α (TNF-α) levels decreased significantly in patients on Px support (day 0 TNF = 415.62 ± 477.80 pg/ml; day 3 TNF = 47.92 ± 27.9 pg/ml; P = 0.0029). There was no significant change in TNF levels in those on quinine alone (day 0 TNF = 477.08 ± 933.90 pg/ml; day 3 TNF = 589 ± 602.3 pg/ml; P > 0.05). There were no serious side-effects necessitating withdrawal of patients receiving Px therapy.

Original languageEnglish (US)
Pages (from-to)680-684
Number of pages5
JournalTropical Medicine and International Health
Volume8
Issue number8
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Cerebral Malaria
Pentoxifylline
Quinine
Coma
Tumor Necrosis Factor-alpha
Therapeutics
Serum

Keywords

  • Human cerebral malaria
  • Pentoxifylline
  • Plasmodium falciparum
  • Quinine dihydrochloride
  • Tumour necrosis factor-α

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Parasitology
  • Immunology

Cite this

Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. / Das, Bidyut Kumar; Mishra, S.; Padhi, P. K.; Ramesh, Manish; Tripathy, Rina; Sahoo, P. K.; Ravindran, B.

In: Tropical Medicine and International Health, Vol. 8, No. 8, 01.08.2003, p. 680-684.

Research output: Contribution to journalArticle

Das, Bidyut Kumar ; Mishra, S. ; Padhi, P. K. ; Ramesh, Manish ; Tripathy, Rina ; Sahoo, P. K. ; Ravindran, B. / Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults. In: Tropical Medicine and International Health. 2003 ; Vol. 8, No. 8. pp. 680-684.
@article{749f6dabba004cf4bde05660fae82d9d,
title = "Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults",
abstract = "Fifty-two adult patients with cerebral malaria were randomly categorized into two groups to receive either quinine dihydrochloride (Qn) alone or a combination of Qn and pentoxifylline (Px). Thirty-two of them received intravenous (i.v.) Qn (group I), and 20 patients (group II) received i.v. Qn along with parenteral Px support (10 mg/kg/day) for the initial 3 days. There was significant improvement in coma resolution time in group II (21.6 ± 13.9 h) in comparison with group I (63.5 ± 19.7 h) (P < 0.001), and mortality was 25{\%} of patients in group I against 10{\%} patients receiving Px adjunct (P > 0.05). Three days post-therapy, serum tumour necrosis factor-α (TNF-α) levels decreased significantly in patients on Px support (day 0 TNF = 415.62 ± 477.80 pg/ml; day 3 TNF = 47.92 ± 27.9 pg/ml; P = 0.0029). There was no significant change in TNF levels in those on quinine alone (day 0 TNF = 477.08 ± 933.90 pg/ml; day 3 TNF = 589 ± 602.3 pg/ml; P > 0.05). There were no serious side-effects necessitating withdrawal of patients receiving Px therapy.",
keywords = "Human cerebral malaria, Pentoxifylline, Plasmodium falciparum, Quinine dihydrochloride, Tumour necrosis factor-α",
author = "Das, {Bidyut Kumar} and S. Mishra and Padhi, {P. K.} and Manish Ramesh and Rina Tripathy and Sahoo, {P. K.} and B. Ravindran",
year = "2003",
month = "8",
day = "1",
doi = "10.1046/j.1365-3156.2003.01087.x",
language = "English (US)",
volume = "8",
pages = "680--684",
journal = "Tropical Medicine and International Health",
issn = "1360-2276",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Pentoxifylline adjunct improves prognosis of human cerebral malaria in adults

AU - Das, Bidyut Kumar

AU - Mishra, S.

AU - Padhi, P. K.

AU - Ramesh, Manish

AU - Tripathy, Rina

AU - Sahoo, P. K.

AU - Ravindran, B.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Fifty-two adult patients with cerebral malaria were randomly categorized into two groups to receive either quinine dihydrochloride (Qn) alone or a combination of Qn and pentoxifylline (Px). Thirty-two of them received intravenous (i.v.) Qn (group I), and 20 patients (group II) received i.v. Qn along with parenteral Px support (10 mg/kg/day) for the initial 3 days. There was significant improvement in coma resolution time in group II (21.6 ± 13.9 h) in comparison with group I (63.5 ± 19.7 h) (P < 0.001), and mortality was 25% of patients in group I against 10% patients receiving Px adjunct (P > 0.05). Three days post-therapy, serum tumour necrosis factor-α (TNF-α) levels decreased significantly in patients on Px support (day 0 TNF = 415.62 ± 477.80 pg/ml; day 3 TNF = 47.92 ± 27.9 pg/ml; P = 0.0029). There was no significant change in TNF levels in those on quinine alone (day 0 TNF = 477.08 ± 933.90 pg/ml; day 3 TNF = 589 ± 602.3 pg/ml; P > 0.05). There were no serious side-effects necessitating withdrawal of patients receiving Px therapy.

AB - Fifty-two adult patients with cerebral malaria were randomly categorized into two groups to receive either quinine dihydrochloride (Qn) alone or a combination of Qn and pentoxifylline (Px). Thirty-two of them received intravenous (i.v.) Qn (group I), and 20 patients (group II) received i.v. Qn along with parenteral Px support (10 mg/kg/day) for the initial 3 days. There was significant improvement in coma resolution time in group II (21.6 ± 13.9 h) in comparison with group I (63.5 ± 19.7 h) (P < 0.001), and mortality was 25% of patients in group I against 10% patients receiving Px adjunct (P > 0.05). Three days post-therapy, serum tumour necrosis factor-α (TNF-α) levels decreased significantly in patients on Px support (day 0 TNF = 415.62 ± 477.80 pg/ml; day 3 TNF = 47.92 ± 27.9 pg/ml; P = 0.0029). There was no significant change in TNF levels in those on quinine alone (day 0 TNF = 477.08 ± 933.90 pg/ml; day 3 TNF = 589 ± 602.3 pg/ml; P > 0.05). There were no serious side-effects necessitating withdrawal of patients receiving Px therapy.

KW - Human cerebral malaria

KW - Pentoxifylline

KW - Plasmodium falciparum

KW - Quinine dihydrochloride

KW - Tumour necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=0042160069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042160069&partnerID=8YFLogxK

U2 - 10.1046/j.1365-3156.2003.01087.x

DO - 10.1046/j.1365-3156.2003.01087.x

M3 - Article

VL - 8

SP - 680

EP - 684

JO - Tropical Medicine and International Health

JF - Tropical Medicine and International Health

SN - 1360-2276

IS - 8

ER -